circumcision and hiv vaccines what are the connections
Download
Skip this Video
Download Presentation
Circumcision and HIV Vaccines: What are the connections?

Loading in 2 Seconds...

play fullscreen
1 / 26

Circumcision and HIV Vaccines: - PowerPoint PPT Presentation


  • 280 Views
  • Uploaded on

Circumcision and HIV Vaccines: What are the connections? Susan Buchbinder, MD HIV Research Section San Francisco Department of Public Health International AIDS Society Meeting Mexico City August 4, 2008 MRKAd5 trivalent vaccine Vaccine: 1:1:1 admixture of 3 Ad5 vectors

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Circumcision and HIV Vaccines: ' - betty_james


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
circumcision and hiv vaccines what are the connections

Circumcision and HIV Vaccines: What are the connections?

Susan Buchbinder, MD

HIV Research Section

San Francisco Department of Public Health

International AIDS Society Meeting

Mexico City

August 4, 2008

mrkad5 trivalent vaccine
MRKAd5 trivalent vaccine
  • Vaccine: 1:1:1 admixture of 3 Ad5 vectors
    • Encoded transgenes: codon-optimized, near-consensus clade B HIV-1 sequences
  • Placebo: vaccine dilution buffer without Ad5
trial design
Trial Design
  • 3000 high-risk HIV uninfected men and women
    • Initial study: 1500 pts w/ Ad5 NAb <200 (Dec 2004)
    • Modification: additional 1500 w/ Ad5 NAb >200 (July 2005)
    • Randomization stratified by Ad5 <18, 19-200, 201-1000, >1000

Primary hypotheses:Ad5 <200 subset

  • Decrease in HIV acquisitionand/or
  • Lower viral load setpoint (∼3 months post-diagnosis)

Secondary hypotheses:Total population

  • Same as primary (Ad5 <200 and Ad5 >200 combined)
slide5

Planned Interim Analysis Results: Ad5<200

MITTAnalysis

HIV Acquisition

Early viral RNA

incidence 95 ci of hiv infection mitt population males
Incidence (95% CI) of HIV Infection MITT population (males)

18 is the LOQ for the Ad5 titer assay; includes all HIV cases thru Oct 17, 2007

baseline characteristics by ad5 status
Baseline characteristics by Ad5 status

p<.05

Baseline Ad5 not associated with HIV in multivariate analysis (p=0.3)

variables included in univariate multivariate analyses
Variables included in univariate/multivariate analyses
  • Vaccine vs. placebo
  • Baseline Ad5
  • Circumcision (self-report)
  • Age
  • Race
  • Region
  • Baseline risk factors (previous 6 months)
    • # male sex partners
    • Unprotected receptive anal sex
    • Unprotected insertive anal sex
    • Substance use
    • Self-reported sexually transmitted infection
variables included in univariate multivariate analyses9
Variables included in univariate/multivariate analyses
  • Vaccine vs. placebo
  • Baseline Ad5*
  • Circumcision (self-report)*
  • Age
  • Race
  • Region
  • Baseline risk factors (previous 6 months)
    • # male sex partners
    • Unprotected receptive anal sex
    • Unprotected insertive anal sex
    • Substance use
    • Self-reported sexually transmitted infection

*significant interaction with vaccine vs. placebo

estimated relative risk of hiv infection vaccine placebo 95 ci
Estimated Relative Risk of HIV Infection Vaccine : Placebo(95% CI)

* Circumcision status was unknown for 49 (2.7%) men. All univariate and multivariate analyses are based on the Cox proportional hazards regression model for time-to-event data.

estimated relative risk of hiv infection vaccine placebo 95 ci11
Estimated Relative Risk of HIV Infection Vaccine : Placebo(95% CI)

* Circumcision status was unknown for 49 (2.7%) men. All univariate and multivariate analyses are based on the Cox proportional hazards regression model for time-to-event data.

estimated relative risk of hiv infection vaccine placebo 95 ci12
Estimated Relative Risk of HIV Infection Vaccine : Placebo(95% CI)

* Circumcision status was unknown for 49 (2.7%) men. All univariate and multivariate analyses are based on the Cox proportional hazards regression model for time-to-event data.

estimated relative risk of hiv infection vaccine placebo 95 ci13
Estimated Relative Risk of HIV Infection Vaccine : Placebo(95% CI)

Men with unknown circumcision status (49, 2.7%) were excluded from analyses. All analyses are based on the Cox proportional hazards regression model for time-to-event data.

association of male circumcision mc with hiv acquisition risk
Association of male circumcision (MC) with HIV acquisition risk
  • Observational studies demonstrate association of MC with reduced HIV acquisition
    • Many studies confirm in heterosexual men
    • Mixed data on role of MC in MSM
  • 3 RCT demonstrate adult MC reduces HIV acquisition risk by >50%
  • Laboratory studies demonstrate role of foreskin in HIV acquisition
    • Keratin layer thin in inner mucosa
    • Target cells abundant in foreskin
    • Possibilities for micro-abrasions
langerhans cells lc in foreskin
Langerhans’ cells (LC) in foreskin
  • In the penis:
  • LC most superficial of all target cells
  • Foreskin has greatest concentration of LC
  • LC most superficial in the inner foreskin
  • Most other target cells also most superficial in the inner foreskin

McCombe AIDS 2006

estimated relative risk of hiv infection vaccine placebo 95 ci18
Estimated Relative Risk of HIV Infection Vaccine : Placebo(95% CI)

Men with unknown circumcision status (49, 2.7%) were excluded from analyses. All analyses are based on the Cox proportional hazards regression model for time-to-event data.

how might these associations of increased risk in uncircumcised men be explained
How might these associations of increased risk in uncircumcised men be explained?
  • (As yet) unmeasured confounders
    • HSV-2, host genetics
    • Sexual networks
    • Sexual risk over time
  • Hypothetical: targeting of activated target cells to mucosa in Ad5 seropositives
    • Make “less risky” sexual practice (insertive anal sex) riskier
  • Next steps:
    • Analyze potential confounders
    • Evaluate cellular and mucosal specimens to explore enhancement
    • Follow study volunteers to evaluate long-term effects
the study volunteers

Acknowledgments

The Study Volunteers

For their dedication and commitment in the search for an HIV vaccine

step study protocol team
Sarah Alexander

Gail Broder

Susan Buchbinder

Lisa Bull

Danny Casimiro

Ann Duerr

Cheryl Ewing

Dan Fitzgerald

Paula Frew

Lori Gabryelski

Peter Gilbert

Tirzah Griffin

Soyon Im

Dale Lawrence

Rosario Leon

David Li

Ellen MacLachlan

Julie McElrath

Devan Mehrotra

Robin Mogg

Dewayne Mullis

Gabriela O’Neill

Mary Pleier

Michael Robertson

Steve Self

Rosario Leon

Amanda Vettori

Steve Wakefield

Amy Zhou

STEP Study Protocol Team
ad